N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide

N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide Chemische Eigenschaften,Einsatz,Produktion Methoden

• Biologische Aktivität

  BMY-25271 is a histamine H2 receptor antagonist.

• in vivo

  BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED ₅₀ values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY- 25271, ranitidine and cimetidine, respectively. Therefore it is about 10 and 74 times more potent than ranitidine and cimetidine, respectively.

• target

  Histamine H2 receptor

N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide Upstream-Materialien And Downstream Produkte

N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(7)Suppliers